- Home
- HAFN vs TVTX Comparison
HAFN vs TVTX Comparison
Compare HAFN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | TVTX |
|---|---|---|
| Founded | 2012 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | HAFN | TVTX |
|---|---|---|
| Price | $6.64 | $27.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.21% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $44.62 |
| Revenue Next Year | N/A | $32.09 |
| P/E Ratio | $11.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.61 | $12.91 |
| 52 Week High | $7.96 | $42.13 |
Technical Indicators
Market Signals| Indicator | HAFN | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.69 | 40.12 |
| Support Level | $6.01 | $26.72 |
| Resistance Level | $7.96 | $31.47 |
| Average True Range (ATR) | 0.24 | 1.20 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 8.36 | 19.76 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.